Back

Impact of sodium-glucose co-transporter 2 inhibition on right ventricular function and pulmonary artery systolic pressure across heart failure phenotypes: a meta-analytic approach

31 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure pharmacotherapy updates Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Marion Patricio

Philippine General Hospital, Manila (Philippines)

3 More presentations in this session

Presentation thumbnail
Safety and efficacy of potassium binders on hyperkalemia: a novel systematic review and meta-analysis of randomized controlled trials
Ms M. Werlang (Rio Do Sul, BR)
Abstract Slides Video
Presentation thumbnail
Gender differences in mortality benefit of raas inhibitors in heart failure: a retrospective cohort study
Doctor V. Copeland (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
6 years of ARNI use in Israel - effectiveness analysis in real world data
Professor Z. Iakobishvili (Tel Aviv, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

31 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
The effects of SGLT2 inhibitors on right ventricle functions in heart failure patients: update meta-analysis of the current literature
thumbnail
Congress Presentation
Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients and a pulmonary artery pressure sensor: does left ventricular ejection fraction matter?
thumbnail
Congress Presentation
Effects of sodium-glucose cotransporter 2 inhibitors on pulmonary hemodynamics in chronic heart failure patients with a pulmonary artery pressure sensor.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources